Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fabentech's Biodefence Antidotes (#1, #2, and #3) are polyclonal antibody-based therapeutics developed to treat poisoning from specific plant-based toxins identified as biological threats. These antidotes are produced using the proprietary FabShield® platform, which generates highly purified equine F(ab')2 fragments. These fragments are designed to provide rapid passive immunity by binding to and neutralizing toxins in the systemic circulation, thereby preventing their toxic effects on cellular targets. While the exact identities of the plant toxins are not publicly disclosed for security reasons, the development of these candidates is currently in the proof-of-concept stage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biodefence Antidote (Plant Toxin).